Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Lung tissue injury relief" refers to the biological processes and molecular pathways activated to restore lung structure and function following injury. Lung repair is coordinated by multiple cell types, notably alveolar epithelial cells (type II pneumocytes, progenitor cells), fibroblasts, and immune cells, and is regulated by growth factors (Epidermal Growth Factor, Fibroblast Growth Factor, Hepatocyte Growth Factor, Vascular Endothelial Growth Factor, Transforming Growth Factor-beta), cytokines (TNF-α, interleukins), chemokines, and extracellular matrix components. Key signaling pathways implicated include Wnt, MAPK, STAT3, and Rho GTPases. The ultimate goal is to regenerate the epithelial barrier, resolve inflammation, and restore function. Disruption or dysregulation of these processes can lead to pathological repair, fibrosis, or chronic lung disease[1][2][3][4][5][6].
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lung tissue injury relief.